Abstract
Head and Neck Squamous Cell Carcinomas (HNSCC) are a collection of tumors located in the upper aerodigestive tract that account for ∼500, 000 new cases annually. Onset of the disease in the population has been attributed to multiple environmental factors. Pathways leading to the development and progression of head and neck squamous cell carcinomas remain largely unknown. Common genetic alterations have been identified, but many of the important genes of activation (oncogenes) or inactivation (tumor suppressor genes) have not yet been identified or characterized. Epigenetic mechanisms, such as histone modifications and DNA methylation, have also become accepted modes of transcriptional inactivation in human malignancies, but are still in their initial stages of evaluation in HNSCC. The majority of DNA methylation studies in HNSCC have focused on genes previously identified as being inactivated in other cancer types. Efforts using genome-wide methylation scanning techniques, such as Restriction Landmark Genomic Scanning (RLGS), have identified novel methylation targets in HNSCC. Due to the involvement of DNA methylation, clinical trials involving demethylating agents, such as Decitabine, alone or in combination with chromatin modifying agents, remain attractive therapeutic options in cancer currently under investigation. Better understanding of the role of DNA methylation in squamous cell carcinomas of the head and neck, as well as the targets of this epigenetic inactivation, may allow for more efficient and earlier detection screenings. In this review, we will discuss our current understanding of epigenetic alterations in HNSCC and their potential use as targets for therapeutic intervention.
Keywords: dna methylation, neck squamous cell carcinomas, aerodigestive tract, epigenetic mechanisms
Current Genomics
Title: DNA Methylation Leaves Its Mark in Head and Neck Squamous Cell Carcinomas (HNSCC)
Volume: 5 Issue: 6
Author(s): L. T. Smith and C. Plass
Affiliation:
Keywords: dna methylation, neck squamous cell carcinomas, aerodigestive tract, epigenetic mechanisms
Abstract: Head and Neck Squamous Cell Carcinomas (HNSCC) are a collection of tumors located in the upper aerodigestive tract that account for ∼500, 000 new cases annually. Onset of the disease in the population has been attributed to multiple environmental factors. Pathways leading to the development and progression of head and neck squamous cell carcinomas remain largely unknown. Common genetic alterations have been identified, but many of the important genes of activation (oncogenes) or inactivation (tumor suppressor genes) have not yet been identified or characterized. Epigenetic mechanisms, such as histone modifications and DNA methylation, have also become accepted modes of transcriptional inactivation in human malignancies, but are still in their initial stages of evaluation in HNSCC. The majority of DNA methylation studies in HNSCC have focused on genes previously identified as being inactivated in other cancer types. Efforts using genome-wide methylation scanning techniques, such as Restriction Landmark Genomic Scanning (RLGS), have identified novel methylation targets in HNSCC. Due to the involvement of DNA methylation, clinical trials involving demethylating agents, such as Decitabine, alone or in combination with chromatin modifying agents, remain attractive therapeutic options in cancer currently under investigation. Better understanding of the role of DNA methylation in squamous cell carcinomas of the head and neck, as well as the targets of this epigenetic inactivation, may allow for more efficient and earlier detection screenings. In this review, we will discuss our current understanding of epigenetic alterations in HNSCC and their potential use as targets for therapeutic intervention.
Export Options
About this article
Cite this article as:
Smith T. L. and Plass C., DNA Methylation Leaves Its Mark in Head and Neck Squamous Cell Carcinomas (HNSCC), Current Genomics 2004; 5 (6) . https://dx.doi.org/10.2174/1389202043348940
DOI https://dx.doi.org/10.2174/1389202043348940 |
Print ISSN 1389-2029 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5488 |
Call for Papers in Thematic Issues
Current Genomics in Cardiovascular Research
Cardiovascular diseases are the main cause of death in the world, in recent years we have had important advances in the interaction between cardiovascular disease and genomics. In this Research Topic, we intend for researchers to present their results with a focus on basic, translational and clinical investigations associated with ...read more
Deep learning in Single Cell Analysis
The field of biology is undergoing a revolution in our ability to study individual cells at the molecular level, and to integrate data from multiple sources and modalities. This has been made possible by advances in technologies for single-cell sequencing, multi-omics profiling, spatial transcriptomics, and high-throughput imaging, as well as ...read more
New insights on Pediatric Tumors and Associated Cancer Predisposition Syndromes
Because of the broad spectrum of children cancer susceptibility, the diagnosis of cancer risk syndromes in children is rarely used in direct cancer treatment. The field of pediatric cancer genetics and genomics will only continue to expand as a result of increasing use of genetic testing tools. It's possible that ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Molecular Targeting of Drug Delivery Systems to Cancer
Current Drug Targets Selumetinib in Advanced Non Small Cell Lung Cancer (NSCLC) Harbouring KRAS Mutation: Endless Clinical Challenge to KRAS-mutant NSCLC.
Reviews on Recent Clinical Trials An Update on the Other Telomerase Inhibitors: Non-G-Quadruplex Interactive Agent, Non-Antisense, Non-Reverse Transcriptase Telomerase Inhibitors
Medicinal Chemistry Reviews - Online (Discontinued) Patent Selections
Recent Patents on Biomarkers HGF Airway Over-expression Leads to Enhanced Pulmonary Vascularization without Induction of VEGF
Current Angiogenesis (Discontinued) Epigenetic Metalloenzymes
Current Medicinal Chemistry Engineered Inorganic Nanoparticles for Drug Delivery Applications
Current Drug Metabolism Therapeutic Potential of Hammerhead Ribozymes in the Treatment of Hyper-Proliferative Diseases
Current Pharmaceutical Biotechnology Recent Developments in Targeted Therapies of the RAF-MEK and PI3KAKT Pathways in Cancer Treatment
Current Cancer Therapy Reviews Diffusion-Weighted MRI for Assessment of Early Cancer Treatment Response
Current Pharmaceutical Biotechnology HGF-Antagonists: Structure, Activities, and Anti-cancer Approach
Current Signal Transduction Therapy Anti-cancer Effects of Metformin: Recent Evidences for its Role in Prevention and Treatment of Cancer
Current Drug Metabolism Integrins in Drug Targeting-RGD Templates in Toxins
Current Pharmaceutical Design Therapeutic Potential, Synthesis, Patent Evaluation and SAR Studies of Thieno[3,2-d]pyrimidine Derivatives: Recent Updates
Current Drug Targets SOCS6 Functions as a Tumor Suppressor by Inducing Apoptosis and Inhibiting Angiogenesis in Human Prostate Cancer
Current Cancer Drug Targets Challenges for Drug Discovery - A Case Study of Urokinase Receptor Inhibition
Combinatorial Chemistry & High Throughput Screening The Urokinase Receptor as a Potential Target in Cancer Therapy
Current Pharmaceutical Design The Immune System of Cancer Patients
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Basal Breast Cancer: A Complex and Deadly Molecular Subtype
Current Molecular Medicine Neuronal Acetylcholine Nicotinic Receptors as New Targets for Lung Cancer Treatment
Current Pharmaceutical Design